Evidence map›Paper›PMID 37428088›Full record

ArticleMicrobiology spectrum2023

Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19.

Thi Thu Thao Dang, Alitzel Anzurez, Kaori Nakayama-Hosoya, Shoji Miki, Kazuo Yamashita, Mark de Souza, Tetsuro Matano, Ai Kawana-Tachikawa

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Thi Thu Thao DangAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Alitzel AnzurezAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Kaori Nakayama-HosoyaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Shoji MikiAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Kazuo YamashitaKOTAI Biotechnologies, Inc., Suita, Japan.
Mark de SouzaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Ai Kawana-TachikawaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-3082-5324
National Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell immunity is crucial for long-term immunological memory, but the profile of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory T cells in individuals who recovered from COVID-19 (COVID-19-convalescent individuals) is not sufficiently assessed. In this study, the breadth and magnitude of SARS-CoV-2-specific T cell responses were determined in COVID-19-convalescent individuals in Japan. Memory T cells against SARS-CoV-2 were detected in all convalescent individuals, and those with more severe disease exhibited a broader T cell response relative to cases with mild symptoms. Comprehensive screening of T cell responses at the peptide level was conducted for spike (S) and nucleocapsid (N) proteins, and regions frequently targeted by T cells were identified. Multiple regions in S and N proteins were targeted by memory T cells, with median numbers of target regions of 13 and 4, respectively. A maximum of 47 regions were recognized by memory T cells for an individual. These data indicate that SARS-CoV-2-convalescent individuals maintain a substantial breadth of memory T cells for at least several months following infection. Broader SARS-CoV-2-specific CD4

Indexed as

COVID-19CD8-Positive T-LymphocytesEpitopes, T-LymphocyteHumansSARS-CoV-2Viral ProteinsEpitopes, T-LymphocyteViral ProteinsCOVID-19SARS-CoV-2T cell immunityvariants

Identifiers

PMID37428088
PMCPMC10433967
OpenAlexW4383710171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.